Retatrutide, also known as LY3437943, is a novel investigational compound developed by Eli Lilly and Company. It is a synthetic peptide designed to target metabolic and weight-related conditions. Structurally, Retatrutide is engineered to mimic certain endogenous hormones that play a role in energy balance and glucose metabolism. The synthesis of Retatrutide involves peptide chemistry techniques that ensure its stability and bioactivity. Researchers have primarily focused on Retatrutide's potential in treating obesity and type 2 diabetes. Clinical studies have observed significant weight loss and improved glycemic control in subjects administered with Retatrutide. These effects are attributed to its action on multiple metabolic pathways, which are crucial in regulating body weight and insulin sensitivity. The mechanism of action of Retatrutide involves the activation of specific receptors that influence metabolic processes. It is believed to act as an agonist at receptors involved in appetite regulation and energy expenditure, thereby promoting weight loss and improving metabolic health. Pharmacokinetic studies of Retatrutide indicate a relatively long half-life, allowing for less frequent dosing. It is stable under physiological conditions and exhibits good bioavailability when administered subcutaneously. However, detailed pharmacokinetic parameters such as exact half-life and bioavailability for other routes are still under investigation. Currently, Retatrutide is in the clinical trial phase, with ongoing studies assessing its efficacy and safety. It has not yet received regulatory approval for clinical use. Researchers continue to explore its potential benefits and long-term effects in metabolic disorders.